RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
18 May 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$43.79
53.2% undervalued intrinsic discount14 Aug
US$20.51
1Y
-9.6%7D
24.9%